Advanced Ovarian Cancer Cases
Wild type
BRCA 1/2
mutation
HR repair
deficiency
Approximately 50% of high-grade serous ovarian tumors are estimated to have a degree of homologous recombination repair deficiency, either germline or somatic mutations, and are likely to benefit from PARP inhibitors.
2